Validated Chiral LC-ESI-MS/MS Method for the Simultaneous Quantification of Darolutamide Diastereomers and Its Active Metabolite in Mice Plasma: Application to a Pharmacokinetic Study

Abstract

A simple, selective and reliable LC-MS/MS method was developed and validated for the simultaneous quantitation of darolutamide diastereomers (diastereomer-1 and diastereomer-2) and its active metabolite i. e. ORM-15341 in mice plasma using warfarin as an internal standard (IS) as per the regulatory guidelines. Plasma samples were extracted by liquid-liquid extraction and the chromatographic separation was achieved on a Chiralpak IA column with an isocratic mobile phase 5 mM ammonium acetate:absolute alcohol (20:80, v/v) at a flow rate of 1.0 mL/min. Detection and quantitation was done by multiple reaction monitoring on a triple quadrupole mass spectrometer following the transitions: m/z 397→202, 395→202 and 307→250 for darolutamide diastereomers, ORM-15341 and the IS, respectively in the negative ionization mode. The calibration curves were linear (r>0.992) in the range of 100–2400 ng/mL for all the analytes. The intra- and inter-day precisions were in the range of 1.25–10.2 and 1.58-12.3; 2.85-5.68 and 1.85-9.58; 2.34-12.1 and 2.58-7.38 for diastereomer-1, diastereomer-2 and ORM-15341, respectively. Both diastereomers and ORM-15341 were found to be stable under different stability conditions. The validated method was applied to a pharmacokinetic study in mice.

Key words

Darolutamide - diastereomers - ORM-15341 - mice plasma - LC-MS/MS - method validation - pharmacokinetics

• References

• 1 Siegel RL, Fedewa SA, Miller KD. et al. Cancer statistics for Hispanics/Latinos. CA Cancer J Clin 2015; 65: 457-480
• 2 Parker C, Gillessen S, Heidenreich A. et al. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl. 05) v69-v77
• 3 Mottet N, Bellmunt J, Bolla M. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618-629
• 4 Saad F, Chi KN, Finelli A. et al. The 2015 CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J 2015; 9: 90-96
• 5 Cookson MS, Lowrance WT, Murad MH. et al. Castration-resistant prostate cancer: AUA guideline amendment. J Urol 2015; 193: 491-499
• 6 Ryan CJ, Cheng MJ. Abiraterone acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2013; 14: 91-96
• 7 Tran C, Ouk S, Clegg NJ. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790
• 8 Clegg NJ, Wongvipat J, Joseph JD. ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72: 1494-1503
• 9 Fizazi K, Massard C, James ND. ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data. Proc Amer Soc Clin Oncol 2013; 31 Abstr 65
• 10 Moilanen A, Riikonen R, Oksala R. ODM-201 – new generation antiandrogen with excellent antiandrogenic and antitumor activity in nonclinical models of CRPC. Eur J Cancer 2013; 49: Abst 685
• 11 Fizazi K, Massard C, Bono P. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): An open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol 2014; 15: 975-985
• 12 Moilanen A, Riikonen R, Oksala R et al. ODM-201 – new generation antiandrogen with excellent antiandrogenic and antitumor activity in nonclinical models of CRPC. Presented at: European Cancer Congress; 2013 Sep 27-Oct 1; Amsterdam, The Netherlands. Abstr E17-2119
• 13 Moilanen AM, Riikonen R, Oksala R. et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 2015; 5: 12007
• 14 Fizazi K, Massard C, Bono P. et al. ARADES study group, Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): An open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol 2014; 15: 975-985
• 15 Taavitsainen P, Prien O, Vuorela A et al.Pharmacokinetics, mass balance, and metabolite profiling of ODM-201 in healthy men: An open-label, phase 1 trial. American Association of Pharmaceutical Scientists 2016; Nov 13-17; Denver, CO. Abstract no: 10W1100. http://abstracts.aaps.org/Verify/AAPS2016/Poster Submissions/10W1100.pdf
• 16 Orion Pharma Clinical Study Code: 3104001/EN3386-201 (accessed on 10 Jan 2018)
• 17 Dittakavi S, Nagasuri PKVSP, Sulochana SP. et al. LC-MS/MS-ESI method for simultaneous quantification of darolutamide and its active metabolite, ORM-15341 in mice plasma and its application to a pharmacokinetic study. J Pharm Biomed Anal 2017; 145: 454-461
• 18 Rej RK, Acharyya RK, Nanda S. Assymetric synthesis of dihydroarteminisic acid through intramolecular Stetter reaction. Tetrahedron 2016; 72: 4931-4937
• 19 US DHHS, FDA, CDER, CVM. Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), 2001, Rockville, MD, USA
• 20 European Medicines Agency. Guideline on Validation of Bioanalytical Methods. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf